DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide

Information source: Geno LLC
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pulmonary Arterial Hypertension

Intervention: Inhaled Nitric Oxide (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Geno LLC

Official(s) and/or principal investigator(s):
Cassie Newell, MAOM, Study Director, Affiliation: Geno LLC

Overall contact:
Robert Roscigno, PhD, Email: Robert.Roscigno@genollc.com


The EAGLE study is a Phase 3, open-label, multi-center, two-part, single-arm study of GeNOsyl(R) delivery system(s) to evaluate if inhaled nitric oxide-induced vasodilation predicts successful wean from parenteral prostacyclin (PGI) in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) undergoing a medically necessary right heart catheterization (RHC). All subjects enrolled in the study will undergo an attempt to wean from parenteral PGI per standard of care.

Clinical Details

Official title: A Phase 3 Open-label Multi-Center, Two-Part Single-arm Study to Evaluate the Acute Vasodilation Response of Inhaled Nitric Oxide as a Predictor of Successful Wean From Parental Prostacyclins in Subjects With Pulmonary Arterial Hypertension

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Primary outcome: Wean Success vs Wean Failure

Detailed description: This study will be divided into 2 parts: a Pilot Phase followed by Pivotal Phase.

- The Pilot Phase will enroll up to 20 subjects. The information derived from the Pilot

Phase will evaluate safety, and assess the vasoreactivity test response rate.

- Approximately 150 subjects will be enrolled in the Pivotal Phase of the study, to

gather further data on weaned successes from parenteral PGI. The Investigator and study staff involved with the wean and patient management will be blinded in this phase of the study to the vasoreactivity results.


Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.


Inclusion Criteria:

- The subject or subject's legally authorized representative signs and dates an

Institutional Review Board (IRB) approved informed consent form prior to the initiation of any study-related activities.

- The subject has been diagnosed with PAH (WHO Group 1) and is WHO Functional Class I

or II at Screening.

- The subject has documented continuous PGI use for ≥ 1 year from Screening, without a

significant interruption (i. e., ≤ 2 day interruption) and without a failed complete wean attempt.

- The subject is a candidate for weaning off parenteral PGI therapy (per Investigator

judgment and standard of care). Exclusion Criteria

- The subject has a hypersensitivity or allergy to ingredients of inhaled nitric oxide

or other clinically significant allergies (clinical significance per Investigator judgment).

- The subject has a PCWP or left ventricular end diastolic pressure (LVEDP) ≥15 mmHg at


- The subject has participated in an investigational product or device study within the

30 days prior to Screening.

Locations and Contacts

Robert Roscigno, PhD, Email: Robert.Roscigno@genollc.com

University of Alabama, Birmingham, Alabama 35294, United States; Recruiting
Leigh Powell, RN, Email: Leigh83@uab.edu
Jose Tallaj, MD, Principal Investigator

Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, United States; Recruiting
Joan Rossi, RN, Email: jrossi1@wpahs.org
Raymond Benza, MD, Principal Investigator

Additional Information

Starting date: June 2015
Last updated: June 29, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017